SPOTLIGHT -
Ms Kuntz is the assistant managing editor of Psychiatric Times.
The New Frontier: Psychedelics as Treatment
New research is being conducted on how psychedelic substances may change the future of mental health care. Dr Carlin explained more in her speech at the Annual Psychiatric Times® World CME Conference™.
Cannabis in Psychiatry: Prominent Issues and Developments
Cannabis and cannabis-derived products are widely debated. Dr Gorelick covered the issues surrounding this substance. Read more for highlights.
Anticipated Phase 3 Interim Results for Sage’s Depression Treatment, Zuranolone
Read about the new results from Sage’s clinical study of depression treatment, zuranolone.
Recent Study Examines Grief in Families of Victims of Terrorist Attacks
Terrorism is a crime from which the families of the victims may never recover. A recent study examines the grieving process in depth.
FDA Advisory Committee Votes in Favor of ALKS 3831
Alkermes plc’s new drug, ALKS 3831, pending FDA approval, could be helpful in the treatment of patients with schizophrenia or bipolar I disorder.
Join Us for the Annual Psychiatric Times® World CME Conference™
The Annual Psychiatric Times® World CME Conference™ is going to be packed full of informative, must-see sessions. Check out this preview of the week's agenda.
Supporting Mental Health Awareness Day
World Mental Health Awareness Day is October 10. Here are some ideas for you to treat yourself while also supporting mental health.
Study Shows Some Reduction in Chronic Pain for Veterans After Decreased Unhealthy Alcohol Use
Veterans with chronic pain should consider reducing alcohol usage to combat symptoms.
Study Shows Importance of Financial Screening to Prevent Suicide Risk in Patients with ADHD
Financial distress in patients with ADHD greatly increases risk of suicide. Read more.